Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Geron Corp (GERN)

Geron Corp (GERN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Geron Corporation (Nasdaq: GERN) today reported that it has granted non-statutory stock options to purchase an aggregate of 200,000 shares of Geron common stock as inducements to three newly-hired employees...

GERN : 1.49 (+0.68%)
Geron Starts Enrollment in Phase III MDS Study on Imetelstat

Geron enrolls first patient in the late-stage IMerge study to evaluate imetelstat in myelodysplastic syndromes.

JNJ : 129.20 (+0.92%)
XLRN : 42.89 (+0.85%)
CELG : 104.70 (+1.26%)
GERN : 1.49 (+0.68%)
Geron Announces First Patient Dosed in IMerge Phase 3 Clinical Trial in Lower Risk Myelodysplastic Syndromes

Geron Corporation (Nasdaq: GERN) today announced that the first patient has been dosed in the IMerge Phase 3 clinical trial to evaluate imetelstat, a first-in-class telomerase inhibitor, in lower risk...

GERN : 1.49 (+0.68%)
Companies Turn to Advanced Therapies to Curb the Spread of Cancer

FinancialBuzz.com News Commentary

ADXS : 0.34 (-4.59%)
GERN : 1.49 (+0.68%)
SLS : 0.13 (unch)
ONPH : 0.0250 (-16.67%)
Companies Turn to Advanced Therapies to Curb the Spread of Cancer

In 2019, the American Cancer Society projected 1.76 million new cancer cases diagnosed and the number of deaths to stand at 606,880 in the U.S. Overall, the alarming projection has caused concern within...

ONPH : 0.0250 (-16.67%)
KDMN : 3.00 (-2.91%)
ADXS : 0.34 (-4.59%)
SLS : 0.13 (unch)
GERN : 1.49 (+0.68%)
Geron's Imetelstat Gets Fast Track Status for Myelofibrosis

Geron's (GERN) sole pipeline candidate, imetelstat, receives Fast Track designation from the FDA for treating relapsed or refractory myelofibrosis. Shares up.

JNJ : 129.20 (+0.92%)
GERN : 1.49 (+0.68%)
CELG : 104.70 (+1.26%)
XLRN : 42.89 (+0.85%)
Biotechs Endeavour to Increase Access to Cancer Treatments

Cancer is the second leading cause of death globally and was responsible for approximately 9.6 million deaths in 2018, according to the World Health Organization (WHO). Statistically, cancer is the cause...

ONPH : 0.0250 (-16.67%)
AGEN : 2.48 (-3.12%)
INO : 2.27 (-2.16%)
GERN : 1.49 (+0.68%)
ACST : 1.97 (-1.01%)
Geron Announces Fast Track Designation Granted to Imetelstat for Relapsed/Refractory Myelofibrosis

Geron Corporation (Nasdaq: GERN) today announced that the United States Food and Drug Administration (FDA) has granted Fast Track designation to imetelstat for the treatment of adult patients with Intermediate-2...

GERN : 1.49 (+0.68%)
Geron to Present at 2019 Cantor Global Healthcare Conference

Geron Corporation (Nasdaq: GERN) today announced that John A. Scarlett, M.D., Chairman and Chief Executive Officer, is scheduled to present a company overview at the 2019 Cantor Global Healthcare Conference...

GERN : 1.49 (+0.68%)
Geron (GERN) Stock Rises 40% in 2019 So Far: Here's Why

Geron (GERN) telomerase inhibitor, imetelstat, is being evaluated in two late-stage studies for patients with MDS and myelofibrosis. The candidate is progressing well in clinical studies.

JNJ : 129.20 (+0.92%)
CELG : 104.70 (+1.26%)
XLRN : 42.89 (+0.85%)
GERN : 1.49 (+0.68%)
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Geron Corporation (Nasdaq: GERN) today reported that it has granted non-statutory stock options to purchase an aggregate of 240,000 shares of Geron common stock as inducements to two newly-hired employees...

GERN : 1.49 (+0.68%)
Geron Starts Phase 3 Clinical Trial in Lower Risk Myelodysplastic Syndromes

Geron Corporation (Nasdaq: GERN) today announced the opening of patient screening and enrollment for the Phase 3 portion of IMerge to evaluate imetelstat, a first-in-class telomerase inhibitor, in lower...

GERN : 1.49 (+0.68%)
Geron (GERN) Stock Up Despite Q2 Earnings & Sales Miss

Geron (GERN) posts a wider-than-expected loss in second-quarter 2019. Operating expenses increase on a year-over-year basis.

JNJ : 129.20 (+0.92%)
ACOR : 2.42 (+1.68%)
GERN : 1.49 (+0.68%)
AXGT : 5.52 (+4.15%)
Geron (GERN) Reports Q2 Loss, Misses Revenue Estimates

Geron (GERN) delivered earnings and revenue surprises of -33.33% and -49.75%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

GERN : 1.49 (+0.68%)
Geron: 2Q Earnings Snapshot

MENLO PARK, Calif. (AP) _ Geron Corp. (GERN) on Thursday reported a loss of $14.2 million in its second quarter.

GERN : 1.49 (+0.68%)
Geron Corporation Reports Second Quarter 2019 Financial Results and Recent Events

Geron Corporation (Nasdaq: GERN) today reported financial results for the second quarter ended June 30, 2019, and recent events. The Company ended the second quarter with $162.3 million in cash and marketable...

GERN : 1.49 (+0.68%)
Geron to Announce Second Quarter Financial Results on August 1, 2019

Geron Corporation (Nasdaq: GERN) today announced that it will release its second quarter 2019 financial results after the market closes on Thursday, August 1, 2019 via press release, which will be available...

GERN : 1.49 (+0.68%)
Geron Enhances Oncology Expertise to Advance Corporate Objectives

Geron Corporation (Nasdaq: GERN) today announced the appointments of Sharon McBain as Vice President, Global Regulatory Affairs and Lynn Bodarky as Vice President, Business Development. These appointments...

AVCO : 1.60 (-4.19%)
GERN : 1.49 (+0.68%)
Geron Appoints Vice President, Human Resources

Geron Corporation (Nasdaq: GERN) today announced the appointment of Shannon Odam as Vice President, Human Resources. Ms. Odam joins other recently recruited senior leadership to further strengthen the...

GERN : 1.49 (+0.68%)
Geron Stock Up More Than 50% in 2019 So Far: Here's Why

Geron (GERN) telomerase inhibitor, imetelstat, is being evaluated in two late stage studies for patients with MDS and myelofibrosis. The candidate is progressing well in clinical studies.

JNJ : 129.20 (+0.92%)
GERN : 1.49 (+0.68%)
XLRN : 42.89 (+0.85%)
CELG : 104.70 (+1.26%)

Van Meerten Stock Picks

The 5 Best Large Caps
I wanted to find which Large Caps had the best momentum so I used Barchart to sort the S&P 500 Large Cap Index first by the highest technical buy signals, then by the most frequent number of new highs in the last month.
CCI -2.05 , AIZ -1.32 , SBAC -0.85 , SO -0.15 , WELL -0.29
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

InsideFutures Commentary

InsideFutures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar